drugset
drugset / Trial / NCT05965479

Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer

NCT05965479 ↗

Phase 2 Recruiting 25 enrolled University of Southampton AstraZeneca · collabNatera, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

Multicentre, single arm, open label UK phase II trial to assess the efficacy of trastuzumab deruxtecan in reducing micrometastatic disease burden in HER2 positive GOA patients who are ctDNA positive after chemotherapy and surgery. 25 patients will be recruited from approximately 15 NHS secondary care sites.

Timeline

Start
2024-04-10
Primary completion
2026-03-31
Completion
2028-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Trastuzumab deruxtecan Monoclonal antibody 4.4 mg/kg Intravenous
Subject Trastuzumab deruxtecan Monoclonal antibody 5.4 mg/kg Intravenous
Subject Trastuzumab deruxtecan Monoclonal antibody 6.4 mg/kg Intravenous

Indications

gastroesophageal adenocarcinoma